Get started
Author

Cynthia X. Ma

Observed names: C X Ma, C.X. Ma, Ma, Cynthia X.
ORCID: 0000-0002-8156-7492
Observed ORCID: 0000-0002-8156-7492
OpenAlex ID: A5136461647
RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies
2021 · Anja van de Stolpe, Wim Verhaegh, et al. · Frontiers in Genetics · 29
PDF
First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations ( ESR1 m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial.
2026 · Francois Clement Bidard, Erica L. Mayer, et al. · Journal of Clinical Oncology · 4
SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer
2026 · François-Clement Bidard, Carlos Barrios, et al. · npj Breast Cancer · 3
PDF
419RO Emergence of ESR1 mutations (ESR1m) in ctDNA during first-line (1L) endocrine-based therapy in HR+/HER2− advanced breast cancer: Findings from the SERENA-6 trial
2026 · F.C. Bidard, Y.H. Park, et al. · ESMO Open · 2
Beyond genomics: biologic insights from the CPTAC proteogenomic analysis of breast cancer
2016 · Sandeep Rajput, Cynthia X. Ma · Translational Cancer Research · 2
Prognostic impact of PIK3CA amplifications and co-occurring mutations detected through circulating tumor DNA (ctDNA) in metastatic breast cancer (MBC).
2026 · Lorenzo Foffano, Andrew A. Davis, et al. · Journal of Clinical Oncology · 1
Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus abemaciclib (ABE) in ER+/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): TACTIVE-U phase 1b/2 results.
2026 · Rachel M. Layman, Katarzyna Joanna Jerzak, et al. · Journal of Clinical Oncology · 1
Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer
2026 · Paul Cottu, Tomas Pascual, et al. · Therapeutic Advances in Medical Oncology
Impact of food access and poverty on somatic genomic profiles and clinical outcomes in metastatic breast cancer.
2026 · Emily L. Podany, Lorenzo Foffano, et al. · Journal of Clinical Oncology
TP53 status and licensing complex/IFNγ transcriptional profiles to stratify endocrine-related outcomes with CDK4/6i exposure in 10,833 real-world ER+/HER2- breast cancers and a treatment-naïve subset.
2026 · Alekya Raghavan, Rosemary N. Plagens, et al. · Journal of Clinical Oncology
Shared and distinct molecular signatures of resistance to different endocrine therapies (Alliance A011106).
2026 · Meenakshi Anurag, Yongchao Dou, et al. · Journal of Clinical Oncology
Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
2026 · Peter Schmid, Cynthia X. Ma, et al. · Clinical Cancer Research
PDF
Updated results and exploratory analysis of ESR1 mutations (ESR1m) circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant+CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients with HR+/HER2- advanced breast cancer (aBC)
2026 · W Janni, F C Bidard, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
532TiP OMNIRAY: A phase I study of the novel GRPR theranostic pair, LY4257529 (diagnostic) and LY4257496 (therapy), in patients with GRPR+ metastatic breast cancer and other advanced solid tumors (Trial in Progress)
2026 · P. Veit-Haibach, K. Jhaveri, et al. · ESMO Open
534TiP Phase I/II study of the novel CDK2 inhibitor ECI830 as a single agent and in combination with ribociclib (RIB) + fulvestrant (FUL) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and advanced solid tumors
2026 · S.C. Lee, T. Koyama, et al. · ESMO Open
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial
2024 · Ma, Cynthia X., Suman, Vera J., et al. · University of Chicago
Works count: 16
Citation count: 42
H-index: 3
I10-index: 1
Year
Topic
Type